This Viewpoint discusses the challenges clinicians face individualizing decisions for patients about the benefits and risks of using aspirin for primary prevention of cardiovascular disease.
This study uses data from a trial comparing clopidogrel and aspirin vs aspirin alone for preventing stroke in patients with TIA to investigate associations between CYP2C19 status and effects of the drugs.
This randomized clinical trial explores the use of aspirin vs placebo as an early intervention for preventing acute respiratory distress syndrome (ARDS) in at-risk patients presenting to the emergency department.
This secondary analysis of data from the Dual Antiplatelet Therapy (DAPT) trial describes development of a risk prediction tool to identify benefits and harms of continuing thienopyridine therapy after an initial year of treatment following percutaneous coronary intervention.
This randomized trial of patients who had no history of migraines compared incidence of migraine attacks between those who used aspirin plus clopidogrel vs aspirin plus placebo for 3 months after undergoing transcatheter atrial septal defect closure.
This genome-wide association study identifies single-nucleotide polymorphisms that influence the association between use of aspirin, nonsteroidal anti-inflammatory drugs, or both and colorectal cancer.
This randomized clinical trial reports that extended treatment with thienopyridine among patients undergoing coronary stent placement with bare metal stent did not result in statistically significant differences in rates of stent thrombosis or major adverse cardiac and cerebrovascular events.
This analysis of data from Danish administrative registries reports that among patients receiving antithrombotic therapy after myocardial infarction, use of nonsteroidal anti-inflammatory drugs was associated with increased risk of bleeding and thrombotic events.
This Viewpoint discusses potental hazards related to the concomitant use of nonsteroidal anti-inflammatory drugs and antithrombotic therapy after myocardial infarction.
Ikeda and coauthors determine whether daily, low-dose aspirin reduces the incidence of cardiovascular (CV) events compared with no aspirin in older Japanese patients with multiple atherosclerotic risk factors.
This Editorial discusses when aspirin should be used to prevent vascular events and the factors that should be discussed in decision making.
This retrospective analysis reports that there were no significant differences between physicians with time-limited vs time-unlimited board certification on 10 primary care performance measures.
This randomized trial reports that among patients undergoing major noncardiac surgery, neither aspirin nor clonidine administered perioperatively reduced the risk of acute kidney injury.
This JAMA Clinical Evidence Synopsis discusses the association of fixed-dose combination therapy (polypill) and a reduced risk for cardiovascular disease (CVD).
Bardach and coauthors assess the effect of a pay-for-performance (P4P) incentives on quality in 84 electronic health record (EHR)–enabled small practices in New York City in the context of an established quality improvement initiative. In an Editorial, Dolor and Schulman discuss the role of financial incentives within primary care practices.